Emerging therapies in bronchiectasis
Oriol Sibila, Lídia Perea, Stefano Aliberti
Abstract
<title>Extract</title> Bronchiectasis is a chronic inflammatory lung disease characterized by abnormal and permanent bronchial dilatation, productive cough, and episodes of worsening symptoms or exacerbations [1]. Despite previously being considered an orphan disease, its global prevalence is increasing, and it is now ranked as the third most common chronic lung disease worldwide, after asthma and Chronic Obstructive Pulmonary Disease (COPD) [2]. Bronchiectasis results in a substantial clinical and socioeconomic burden on patients, families, and healthcare systems [3], and current management strategies primarily focus on symptom control, treating the airway infection and the underlying cause when identifiable, promoting airway clearance, and preventing exacerbations [4, 5]. On August 12th 2025, FDA approved brensocatib, an oral anti-inflammatory molecule, as the first drug specifically approved for children 12 years and older and adults with bronchiectasis. This fact represents a hallmark in the history of bronchiectasis, and several other new pharmacological treatments are being tested or will be tested soon. Here, we review all of the new emerging therapies in bronchiectasis, including both novel anti-inflammatory and anti-infective agents.